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L1 and L2 (lasso loop) connect the PDE domain to the SMB2 domain at the N-terminal end of the chain and to the nuclease-like domain at the C-terminal end.
In vitro substrate specificity of the ATX catalytic core is broad. ATX hydrolyzes phosphodiester bonds at the 5'-end of various oligonucleotide substrates, acts as an ATPase/GTPase by catalyzing bilateral hydrolysis of either ATP or GTP 5' beta-phosphates, hydrolyzes the AMP group from the NAD molecule, and functions as an ATP pyrophosphatase by removing the entire pyrophosphate group from nucleoside phosphate molecules (3) . The threonine residue (T210) in the middle of the PDE catalytic domain serves as a point of transient binding of reaction intermediates (17) and provides a fulcrum for catalytic activity (18). All of the enzymatic activities of ATX are dependent on the concentration of divalent cations (19).
Ten years after its initial discovery, ATX was purified from human plasma and shown to have lysophospholipase D (LysoPLD) enzymatic activity, catalyzing the hydrolysis of the distal phosphoester bond that connects monoacylglycerol phosphates to the polar head group of lysophospholipids (10, 20).
In this respect ATX is an atypical member of the NPP family, as none of the other paralogues efficiently hydrolyze lysophospholipids. A particularly low Michaelis constant for lysophosphatidylcholine (LPC), a lysolipid present at high concentrations in plasma and other tissues, suggests that the primary physiological function of ATX in the body is to promote the conversion of LPC to lysophosphatidic acid (LPA), a bioactive lipid involved in multiple key physiological and pathological processes (21-25).
Madan D. and colleagues have shown that it is possible to directly assess lysoPLD activity in vivo by measuring the enzymatic turnover of a fluorogenic LPC-like substrate in breast cancer xenografts with high ATX expression (26) Numerous studies have defined several key biochemical and structural features responsible for stability, rate of catalysis, and substrate specificity of ATX. For instance, regions located in close proximity of the catalytic cleft (27) or at the edges of the polypeptide chain (28) were recognized as being critical for both substrate docking and the dynamic interplay between divalent cations and T210 during catalysis. The nuclease-like domain of ATX helps to stabilize the catalytic reaction via direct calcium- Early studies showed that proteins with high carbohydrate-binding affinity binds ATX and that N-glycosidase treatment induces a shift of ATX molecular mass on SDS-PAGE, indicating the presence of glycosylated post-translational modifications at asparagine residues (31). The carbohydrate moiety is important in secretion (see Section 3) and activity of the enzyme (32). Among various aminoglycoside chains, N-acetylglucosamine mannose (Man8/9GlcNAc2), a sugar moiety rather uncommon in eukaryotes, and N-acetylglucosamine (GlcNAc2) attached to asparagine residues 524 and 53, respectively, are critical for optimal enzyme function (15, 33). Molecular dynamic simulations of folding trajectories of engineered ATX lacking either the nuclease-like domain or the glycans suggested that these structural elements are essential in maintaining the T210 residue in the correct position (34).
The crystallization and extensive analysis of rat and mouse ATX, which exhibit a high degree of sequence homology with the human protein, provided the first clear glimpse into the mechanism of substrate recognition and catalysis of the enzyme (15, 16, 35) . These studies showed that numerous disulfide and hydrogen bonds cooperate to bring the SMB-like motifs, the central PDE catalytic core, and nuclease-like domain together to form a lipophilic pocket adjacent to the catalytic site. It is believed that the size of the lipophilic pocket underlies the key difference between ATX and the other NPP members in terms of substrate specificity, whereby the ATX binding pocket appears to selectively accommodate fatty acid moieties of lysolipid substrates.
SMB-like domains in ATX do not appear to mediate homodimerization as previously reported for other NPP family members (30), but rather they preserve the characteristic disulfide-bonded knot folds typical of these structures (15). In addition, SMB2 contains an RGD motif, a tripeptide (Arg-Gly-Asp) with high binding affinity for PAI-1 (36, 37) and integrins (38). Since SMB-like domains are in close proximity to a hydrophobic channel connecting the catalytic site to the external environment, they are believed to act as a bridge between ATX and the extracellular space where enzymatic products can directly interact with their cognate receptors (16). This view is supported by studies in platelets and mammalian cells showing that both SMB-like domains and integrins are required for the interaction of ATX with platelets and that integrin activation increases ATX-dependent LPA production (39). The wealth of information available on both enzymatic dynamics and ATX structure is helping to establish new operative frameworks for inhibitor design which will hopefully lead to the synthesis of potent and selective molecules capable of effectively inhibiting ATX function in the context of cancer and other pathologies where its activity is dysregulated (see Section 4).
Transcriptional control and secretion
The regulatory mechanism(s) that controls ENPP2 gene expression have not been extensively Currently, the process that leads to ATX secretion is considerably better understood than the dynamics of its expression. Sequence similarity between ATX and NPP1, the closest related member of the NPP family, led to the initial idea that ATX is a type II transmembrane protein firmly anchored at the plasma membrane from which it is released into the extracellular space via proteolytic cleavage (52). On the contrary, careful molecular studies revealed that ATX localizes to the Golgi-apparatus and contains both a consensus-sequence for furin-dependent cleavage and a 27-amino acid residue signal peptide at the N-terminus, suggesting that the protein is synthetized as a pre-pro-enzyme that is proteolytically cleaved in the endomembrane system before secretion (53, 54). Interestingly, current evidence indicates that Nglycosylation and the nuclease-like domain (29) are two important factors mediating ATX secretion (32).
ATX is detected in various biological fluids and tissues including plasma (50, 59-61), placenta, ovary, small intestine (2), platelets (55), adipose tissue (56-59), nervous system (4, 60-63), and cerebrospinal fluid (64). In mice, both conditional gene knockout in adipose tissue and global Enpp2 heterozygosity result in a 50% decrease in ATX levels or activity in plasma (57), indicating that circulating ATX is predominately produced in adipose tissue and further that it is the primary enzyme responsible for maintaining circulating LPA levels.
Although it has been shown in mice that ATX can be rapidly eliminated from the circulation through a potential scavenger receptor-mediated process taking place in liver sinusoidal endothelial cells (65), the mechanisms that control ATX clearance remain poorly understood. Nonetheless, the multiorgan origin and complex regulatory dynamics controlling ATX concentration in tissues strongly suggest that aberrant ATX homeostasis may foster conditions that lead to pathological states. As discussed in the next section, there is overwhelming evidence that anomalous ATX activity leads to oncogenesis and cancer progression. 
Role in physiology and cancer pathophysiology
All crucial residues and structural elements of ENPP2 are conserved between humans and mice (35), which is arguably a testament to the fundamental importance of this gene in mammalian physiology.
Although ATX can also act on sphingosylphosphorylcholine to produce sphingosine-1-phosphate, a modulator of cell motility and other biological functions (66), it is broadly accepted that the majority of biological effects are mediated through the production of the bioactive lipid mediator LPA. Although ATX is not the only source of LPA production (67), measurements in mice with either systemic or targeted heterozygous deletion of the ENPP2 gene or transgenic over-expression of the human ENPP2 gene established that ATX is a dominant physiological source of circulating bioactive LPA (68). For this reason, ATX-mediated LPA production and signal transduction through LPA-specific G protein-coupled receptors is commonly referred to as the ATX/LPA-signaling axis (69-71).
The ATX polypeptide chain contains multiple domains that could potentially modulate biological activities independent of enzymatic function. For instance, the structural homology of SMB-like domains with SMB, a short peptide derived from the proteolytic cleavage of vitronectin, suggests that these motifs may be able to regulate cell adhesion and extracellular matrix dynamics similarly to vitronectin (72, 73).
In support of this hypothesis, it has been shown that SMB binds to the urokinase receptor and the plasminogen activator inhibitor-1 (PAI-1) (36) and that SMB-like-dependent ATX binding to integrins modulates motogenic activity of both cancer and mouse aortic vascular smooth muscle cells (74) .
Similarly to morphogens that modulate key aspects of both development and cancer progression as a consequence of spatiotemporal regulation (75) , properly regulated expression and activity of ATX is crucial for embryogenesis (76) . A number of studies have shown that ATX controls embryonic development by regulating vasculature maturation and angiogenesis. Homozygous deletion of the ENPP2 gene in mice results in embryonic lethality due to defective blood vessel formation and growth (68, 77).
The effect is dependent on the integrity of the PDE domain because embryonic lethality is still observed in mice expressing ATX (T210A), a catalytically inactive version of the enzyme generated by substituting an alanine in place of the central threonine (78) . It has been shown that ATX regulates both prenatal Neoplastic diseases often arise at sites of persistent inflammation and several inflammatory conditions are known to predispose to cancer (127, 128) . Many studies have established ATX as a key regulator of inflammatory response at multiple levels that is required for proper maintenance of immune system homeostasis (129-131). For example, ATX binding to chemokine-activated lymphocytes is associated with increased immune cell homing to lymphoid vessels, and intravenous injection of enzymatically inactive ATX attenuates this process (132) . Similarly, it has been reported that ATX both controls lymphocyte migration across the basal lamina of lymphatic high endothelial venules through a myosin II-dependent mechanism (133) , and regulates the rate of in vivo T-cell transendothelial migration that copy number alterations and mutations in ATX are present in ovarian serous cystadenocarcinoma (33% altered), breast invasive carcinoma (20% altered), liver hepatocellular carcinoma (20% altered), lung adenocarcinoma (11% altered), bladder urothelial carcinoma (10% altered), and head and neck squamous cell carcinoma (10% altered) patient tumors (Fig. 2) collected and analyzed by The Cancer
Genome Atlas project (158) (159) (160) (161) (162) (163) . Most of these alterations are ENPP2 amplifications, which could potentially underlie dysregulation of ATX/LPA-mediated signaling pathways in these diseases.
Mutations are rare and usually non-recurrent. The greatest frequency of ENPP2 mutations is seen in lung adenocarcinoma (4.7% of all patient tumors have at least one ENPP2 mutation), followed by head and neck squamous cell carcinoma (2%), ovarian serous cystadenocarcinoma (1%), breast invasive carcinoma (0.8%), bladder urothelial carcinoma (0.8%), and liver hepatocellular carcinoma (0.5%). Follow-up studies are warranted to determine whether these mutations induce functional changes that may promote tumor development and growth. Further, additional analysis is needed to determine whether other pathway alterations may serve compensatory roles in the small set of patients with ENPP2 deletions.
Together, these results indicate that the ATX/LPA signaling axis may be dysregulated in specific cancer subtypes and that patients could potentially benefit from targeted therapies blocking ATX/LPA signaling Due to the pleiotropic connection of ATX in cancer pathology, considerable effort has been made to generate small molecule inhibitors that target its enzymatic activity (120, (164) (165) (166) (167) (168) (169) (170) (171) (172) (173) . 
Conclusions and perspectives
Overwhelming evidence suggests that anomalous ATX activity contributes to the development of favorable conditions for neoplastic disease initiation and progression. The significance of ATX in mammalian physiology is highlighted by the fact that embryos cannot develop in the absence of ENPP2
and that all key biochemical/structural features required for optimal enzymatic activity remained evolutionarily conserved since human and mouse species diverged from their common ancestor.
Although much has been discovered regarding ATX structure and its pathophysiological significance, several questions remain to be answered. 
